CD8B and lymphoma: To assess the efficacy of systemic CpG(B)-STAT3dODN administration on OCI-Ly3 lymphoma, the immunodeficient NSG mice with established, disseminated-luciferase-expressing OCI-Ly3 lymphoma were treated using intravenous (i.v.)injections of 10 mg/kg CpG(B)-STAT3dODN, CpG(B)-scrODN, or only PBS for 10 days.